{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:33:47Z","timestamp":1794051227815,"version":"4.8.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["670261"],"award-info":[{"award-number":["670261"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"crossref","award":["126"],"award-info":[{"award-number":["126"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"crossref"}]},{"name":"John and Birthe Meyer Foundation","id":[{"id":"https:\/\/ror.org\/03j077d81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Council of the Capital Region of Denmark","id":[{"id":"https:\/\/ror.org\/049qz7x77","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF18OC0033926"],"award-info":[{"award-number":["NNF18OC0033926"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A comprehensive literature reports on the correlation between elevated levels of urokinase-type plasminogen activator receptor (uPAR) and the severity of diseases with chronic inflammation including solid cancers. Molecular imaging is widely used as a non-invasive method to locate disease dissemination via full body scans and to stratify patients for targeted treatment. To date, the only imaging probe targeting uPAR that has reached clinical phase-II testing relies on a high-affinity 9-mer peptide (AE105), and several studies by positron emission tomography (PET) scanning or near-infra red (NIR) fluorescence imaging have validated its utility and specificity in vivo. While our previous studies focused on applying various reporter groups, the current study aims to improve uPAR-targeting properties of AE105. We successfully stabilized the small uPAR-targeting core of AE105 by constraining its conformational landscape by disulfide-mediated cyclization. Importantly, this modification mitigated the penalty on uPAR-affinity typically observed after conjugation to macrocyclic chelators. Cyclization did not impair tumor targeting efficiency of AE105 in vivo as assessed by PET imaging and a trend towards increased tracer uptake was observed. In future studies, we predict that this knowledge will aid development of new fluorescent AE105 derivatives with a view to optical imaging of uPAR to assist precision guided cancer surgery.<\/jats:p>","DOI":"10.1038\/s41598-023-43934-w","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T14:10:49Z","timestamp":1697033449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeted imaging of uPAR expression in vivo with cyclic AE105 variants"],"prefix":"10.1038","volume":"13","author":[{"given":"Julie Maja","family":"Leth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella Anne","family":"Newcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise","family":"Gr\u00f8nnemose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Tranekj\u00e6r","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Qvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Skovsbo","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Bruhn Schneider","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe Brandt","family":"Kragelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J\u00f8rgen Dyreborg","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ploug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"43934_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/S0021-9258(18)52382-6","volume":"266","author":"M Ploug","year":"1991","unstructured":"Ploug, M. et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266, 1926\u20131933 (1991).","journal-title":"J Biol Chem"},{"key":"43934_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112760","author":"JM Leth","year":"2019","unstructured":"Leth, J. M. et al. Evolution and Medical Significance of LU Domain-Containing Proteins. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms20112760 (2019).","journal-title":"Int J Mol Sci"},{"key":"43934_CR3","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2010-03-276642","volume":"116","author":"BM Connolly","year":"2010","unstructured":"Connolly, B. M. et al. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 116, 1593\u20131603. https:\/\/doi.org\/10.1182\/blood-2010-03-276642 (2010).","journal-title":"Blood"},{"key":"43934_CR4","doi-asserted-by":"publisher","first-page":"33544","DOI":"10.1074\/jbc.M111.220087","volume":"286","author":"H Gardsvoll","year":"2011","unstructured":"Gardsvoll, H. et al. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. J Biol Chem 286, 33544\u201333556. https:\/\/doi.org\/10.1074\/jbc.M111.220087 (2011).","journal-title":"J Biol Chem"},{"key":"43934_CR5","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.15252\/embj.201387611","volume":"33","author":"GM Ferraris","year":"2014","unstructured":"Ferraris, G. M. et al. The interaction between uPAR and vitronectin triggers ligand-independent adhesion signalling by integrins. EMBO J 33, 2458\u20132472. https:\/\/doi.org\/10.15252\/embj.201387611 (2014).","journal-title":"EMBO J"},{"key":"43934_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1083\/jcb.200612058","volume":"177","author":"CD Madsen","year":"2007","unstructured":"Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O. & Sidenius, N. uPAR-induced cell adhesion and migration: Vitronectin provides the key. J Cell Biol 177, 927\u2013939. https:\/\/doi.org\/10.1083\/jcb.200612058 (2007).","journal-title":"J Cell Biol"},{"key":"43934_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.15252\/embr.201541681","volume":"17","author":"V De Lorenzi","year":"2016","unstructured":"De Lorenzi, V. et al. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin. EMBO Rep 17, 982\u2013998. https:\/\/doi.org\/10.15252\/embr.201541681 (2016).","journal-title":"EMBO Rep"},{"key":"43934_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780641","volume":"12","author":"LJH Rasmussen","year":"2021","unstructured":"Rasmussen, L. J. H., Petersen, J. E. V. & Eugen-Olsen, J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol 12, 780641. https:\/\/doi.org\/10.3389\/fimmu.2021.780641 (2021).","journal-title":"Front Immunol"},{"key":"43934_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835929","volume":"12","author":"E Minaei","year":"2022","unstructured":"Minaei, E. et al. Cancer progression gene expression profiling identifies the urokinase plasminogen activator receptor as a biomarker of metastasis in cutaneous squamous cell carcinoma. Front Oncol 12, 835929. https:\/\/doi.org\/10.3389\/fonc.2022.835929 (2022).","journal-title":"Front Oncol"},{"key":"43934_CR10","doi-asserted-by":"publisher","first-page":"117727191771544","DOI":"10.1177\/1177271917715443","volume":"12","author":"SW de Geus","year":"2017","unstructured":"de Geus, S. W. et al. Prognostic impact of urokinase plasminogen activator receptor expression in pancreatic cancer: Malignant versus stromal cells. Biomark Insights 12, 1177271917715443. https:\/\/doi.org\/10.1177\/1177271917715443 (2017).","journal-title":"Biomark Insights"},{"key":"43934_CR11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jnci\/91.10.869","volume":"91","author":"RW Stephens","year":"1999","unstructured":"Stephens, R. W. et al. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis. J Natl Cancer Inst 91, 869\u2013874. https:\/\/doi.org\/10.1093\/jnci\/91.10.869 (1999).","journal-title":"J Natl Cancer Inst"},{"key":"43934_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa1911481","volume":"382","author":"SS Hayek","year":"2020","unstructured":"Hayek, S. S. et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med 382, 416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa1911481 (2020).","journal-title":"N Engl J Med"},{"key":"43934_CR13","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2174\/1389450120666181204164140","volume":"20","author":"BJ Buckley","year":"2019","unstructured":"Buckley, B. J., Ali, U., Kelso, M. J. & Ranson, M. The urokinase plasminogen activation system in rheumatoid arthritis: Pathophysiological roles and prospective therapeutic targets. Curr Drug Targets 20, 970\u2013981. https:\/\/doi.org\/10.2174\/1389450120666181204164140 (2019).","journal-title":"Curr Drug Targets"},{"key":"43934_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1182\/bloodadvances.2016004002","volume":"1","author":"S Thornton","year":"2017","unstructured":"Thornton, S. et al. Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells. Blood Adv 1, 545\u2013556. https:\/\/doi.org\/10.1182\/bloodadvances.2016004002 (2017).","journal-title":"Blood Adv"},{"key":"43934_CR15","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1182\/blood.V96.13.4091","volume":"96","author":"N Sidenius","year":"2000","unstructured":"Sidenius, N. et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 96, 4091\u20134095 (2000).","journal-title":"Blood"},{"key":"43934_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738093","volume":"12","author":"J Sarif","year":"2021","unstructured":"Sarif, J. et al. Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19. Front Immunol 12, 738093. https:\/\/doi.org\/10.3389\/fimmu.2021.738093 (2021).","journal-title":"Front Immunol"},{"key":"43934_CR17","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1161\/strokeaha.112.664094","volume":"43","author":"A Edsfeldt","year":"2012","unstructured":"Edsfeldt, A. et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43, 3305\u20133312. https:\/\/doi.org\/10.1161\/strokeaha.112.664094 (2012).","journal-title":"Stroke"},{"key":"43934_CR18","doi-asserted-by":"publisher","first-page":"16886","DOI":"10.1074\/jbc.270.28.16886","volume":"270","author":"TH Bugge","year":"1995","unstructured":"Bugge, T. H. et al. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270, 16886\u201316894. https:\/\/doi.org\/10.1074\/jbc.270.28.16886 (1995).","journal-title":"J Biol Chem"},{"key":"43934_CR19","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1073\/pnas.93.12.5899","volume":"93","author":"TH Bugge","year":"1996","unstructured":"Bugge, T. H. et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci U S A 93, 5899\u20135904. https:\/\/doi.org\/10.1073\/pnas.93.12.5899 (1996).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43934_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.drudis.2021.01.016","volume":"26","author":"C Yuan","year":"2021","unstructured":"Yuan, C., Guo, Z., Yu, S., Jiang, L. & Huang, M. Development of inhibitors for uPAR: Blocking the interaction of uPAR with its partners. Drug Discov Today 26, 1076\u20131085. https:\/\/doi.org\/10.1016\/j.drudis.2021.01.016 (2021).","journal-title":"Drug Discov Today"},{"key":"43934_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030498","author":"MT Masucci","year":"2022","unstructured":"Masucci, M. T., Minopoli, M., Di Carluccio, G., Motti, M. L. & Carriero, M. V. Therapeutic strategies targeting urokinase and its receptor in cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers14030498 (2022).","journal-title":"Cancers."},{"key":"43934_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215376","author":"V Metrangolo","year":"2021","unstructured":"Metrangolo, V., Ploug, M. & Engelholm, L. H. The urokinase receptor (uPAR) as a \u201cTrojan Horse\u201d in targeted cancer therapy: Challenges and opportunities. Cancers https:\/\/doi.org\/10.3390\/cancers13215376 (2021).","journal-title":"Cancers"},{"key":"43934_CR23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.nucmedbio.2012.05.007","volume":"39","author":"M Persson","year":"2012","unstructured":"Persson, M., Rasmussen, P., Madsen, J., Ploug, M. & Kjaer, A. New peptide receptor radionuclide therapy of invasive cancer cells: In vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol 39, 962\u2013969. https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.05.007 (2012).","journal-title":"Nucl Med Biol"},{"key":"43934_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132. https:\/\/doi.org\/10.1038\/s41586-020-2403-9 (2020).","journal-title":"Nature"},{"key":"43934_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040054","author":"ET Harel","year":"2019","unstructured":"Harel, E. T. et al. Antibody-drug conjugates targeting the Urokinase Receptor (uPAR) as a possible treatment of aggressive breast cancer. Antibodies https:\/\/doi.org\/10.3390\/antib8040054 (2019).","journal-title":"Antibodies"},{"key":"43934_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1073\/pnas.0236849100","volume":"100","author":"S Liu","year":"2003","unstructured":"Liu, S., Aaronson, H., Mitola, D. J., Leppla, S. H. & Bugge, T. H. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 100, 657\u2013662. https:\/\/doi.org\/10.1073\/pnas.0236849100 (2003).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43934_CR27","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1002\/anie.201510866","volume":"55","author":"AF Rullo","year":"2016","unstructured":"Rullo, A. F. et al. Re-engineering the immune response to metastatic cancer: Antibody-recruiting small molecules targeting the urokinase receptor. Angew Chem Int Ed Engl 55, 3642\u20133646. https:\/\/doi.org\/10.1002\/anie.201510866 (2016).","journal-title":"Angew Chem Int Ed Engl"},{"key":"43934_CR28","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1021\/mp500177c","volume":"11","author":"M Persson","year":"2014","unstructured":"Persson, M. et al. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. Mol Pharm 11, 2796\u20132806. https:\/\/doi.org\/10.1021\/mp500177c (2014).","journal-title":"Mol Pharm"},{"key":"43934_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1021\/acs.molpharmaceut.2c00297","volume":"20","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Nafamostat mesylate in combination with the mouse amino-terminal fragment of urokinase-human serum albumin improves the treatment outcome of triple-negative breast cancer therapy. Mol Pharm 20, 905\u2013917. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00297 (2023).","journal-title":"Mol Pharm"},{"key":"43934_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.732015","volume":"9","author":"JM Leth","year":"2021","unstructured":"Leth, J. M. & Ploug, M. Targeting the urokinase-type plasminogen activator receptor (uPAR) in human diseases with a view to non-invasive imaging and therapeutic intervention. Front Cell Dev Biol 9, 732015. https:\/\/doi.org\/10.3389\/fcell.2021.732015 (2021).","journal-title":"Front Cell Dev Biol"},{"key":"43934_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.12956","volume":"5","author":"M Persson","year":"2015","unstructured":"Persson, M. et al. First-in-human uPAR PET: Imaging of cancer aggressiveness. Theranostics 5, 1303\u20131316. https:\/\/doi.org\/10.7150\/thno.12956 (2015).","journal-title":"Theranostics"},{"key":"43934_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2967\/jnumed.110.083386","volume":"53","author":"M Persson","year":"2012","unstructured":"Persson, M. et al. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: Implications for visualizing cancer invasion. J Nucl Med 53, 138\u2013145. https:\/\/doi.org\/10.2967\/jnumed.110.083386 (2012).","journal-title":"J Nucl Med"},{"key":"43934_CR33","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.7150\/thno.49787","volume":"11","author":"S Kurbegovic","year":"2021","unstructured":"Kurbegovic, S. et al. IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts. Theranostics 11, 7159\u20137174. https:\/\/doi.org\/10.7150\/thno.49787 (2021).","journal-title":"Theranostics"},{"key":"43934_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-021-01657-2","author":"VM Baart","year":"2021","unstructured":"Baart, V. M. et al. Side-by-side comparison of uPAR-targeting optical imaging antibodies and antibody fragments for fluorescence-guided surgery of solid tumors. Mol Imaging Biol https:\/\/doi.org\/10.1007\/s11307-021-01657-2 (2021).","journal-title":"Mol Imaging Biol"},{"key":"43934_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oraloncology.2016.12.026","volume":"66","author":"MC Boonstra","year":"2017","unstructured":"Boonstra, M. C. et al. Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer. Oral Oncol 66, 1\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.12.026 (2017).","journal-title":"Oral Oncol"},{"key":"43934_CR36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00055","author":"AA Kumar","year":"2023","unstructured":"Kumar, A. A., Vine, K. L. & Ranson, M. Recent advances in targeting the urokinase plasminogen activator with nanotherapeutics. Mol Pharm https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00055 (2023).","journal-title":"Mol Pharm"},{"key":"43934_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.atherosclerosis.2022.03.026","volume":"352","author":"HA Khare","year":"2022","unstructured":"Khare, H. A. et al. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [(64)Cu]Cu-DOTA-AE105 positron emission tomography (PET). Atherosclerosis 352, 103\u2013111. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.026 (2022).","journal-title":"Atherosclerosis"},{"key":"43934_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2967\/jnumed.121.262866","volume":"63","author":"LM Ris\u00f8r","year":"2022","unstructured":"Ris\u00f8r, L. M. et al. Prognostic value of urokinase-type plasminogen activator receptor PET\/CT in head and neck squamous cell carcinomas and comparison with (18)F-FDG PET\/CT: A single-center prospective study. J Nucl Med 63, 1169\u20131176. https:\/\/doi.org\/10.2967\/jnumed.121.262866 (2022).","journal-title":"J Nucl Med"},{"key":"43934_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061087","author":"MO Fosbol","year":"2021","unstructured":"Fosbol, M. O. et al. uPAR PET\/CT for prognostication and response assessment in patients with metastatic castration-resistant prostate cancer undergoing radium-223 therapy: A prospective phase II study. Diagnostics https:\/\/doi.org\/10.3390\/diagnostics11061087 (2021).","journal-title":"Diagnostics"},{"key":"43934_CR40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.121.263177","volume":"63","author":"EA Carlsen","year":"2022","unstructured":"Carlsen, E. A. et al. Prospective Phase II trial of prognostication by (68)Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR-targeted therapy. J Nucl Med 63, 1371\u20131377. https:\/\/doi.org\/10.2967\/jnumed.121.263177 (2022).","journal-title":"J Nucl Med"},{"key":"43934_CR41","doi-asserted-by":"publisher","first-page":"15407","DOI":"10.18632\/oncotarget.14282","volume":"8","author":"A Christensen","year":"2017","unstructured":"Christensen, A. et al. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model. Oncotarget 8, 15407\u201315419. https:\/\/doi.org\/10.18632\/oncotarget.14282 (2017).","journal-title":"Oncotarget"},{"key":"43934_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00701-021-05051-3","volume":"164","author":"J Skjoth-Rasmussen","year":"2022","unstructured":"Skjoth-Rasmussen, J. et al. A new uPAR-targeting fluorescent probe for optical guided intracranial surgery in resection of a meningioma: A case report. Acta Neurochir (Wien) 164, 267\u2013271. https:\/\/doi.org\/10.1007\/s00701-021-05051-3 (2022).","journal-title":"Acta Neurochir (Wien)"},{"key":"43934_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1121143","volume":"311","author":"Q Huai","year":"2006","unstructured":"Huai, Q. et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 311, 656\u2013659. https:\/\/doi.org\/10.1126\/science.1121143 (2006).","journal-title":"Science"},{"key":"43934_CR44","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jmb.2015.01.022","volume":"427","author":"B Zhao","year":"2015","unstructured":"Zhao, B. et al. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. J Mol Biol 427, 1389\u20131403. https:\/\/doi.org\/10.1016\/j.jmb.2015.01.022 (2015).","journal-title":"J Mol Biol"},{"key":"43934_CR45","doi-asserted-by":"publisher","first-page":"34304","DOI":"10.1074\/jbc.M112.398404","volume":"287","author":"HD Mertens","year":"2012","unstructured":"Mertens, H. D. et al. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). J Biol Chem 287, 34304\u201334315. https:\/\/doi.org\/10.1074\/jbc.M112.398404 (2012).","journal-title":"J Biol Chem"},{"key":"43934_CR46","doi-asserted-by":"publisher","first-page":"43515","DOI":"10.1074\/jbc.M111.300020","volume":"286","author":"H Gardsvoll","year":"2011","unstructured":"Gardsvoll, H. et al. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem 286, 43515\u201343526. https:\/\/doi.org\/10.1074\/jbc.M111.300020 (2011).","journal-title":"J Biol Chem"},{"key":"43934_CR47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01663","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Structural dynamics-driven discovery of anticancer and antimetastatic effects of diltiazem and glibenclamide targeting urokinase receptor. J Med Chem https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01663 (2023).","journal-title":"J Med Chem"},{"key":"43934_CR48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA1119.007847","author":"JM Leth","year":"2019","unstructured":"Leth, J. M., Mertens, H. D., Leth-Espernsen, K. Z., J\u00f8rgensen, T. J. D. & Ploug, M. Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?. J Biol Chem https:\/\/doi.org\/10.1074\/jbc.RA1119.007847 (2019).","journal-title":"J Biol Chem"},{"key":"43934_CR49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00759","author":"M Arancillo","year":"2022","unstructured":"Arancillo, M., Lin, C. M. & Burgess, K. Piptide chemotypes for perturbation of the interaction of urokinase with its receptor. J Med Chem https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00759 (2022).","journal-title":"J Med Chem"},{"key":"43934_CR50","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1021\/acsmedchemlett.0c00422","volume":"12","author":"K Bum-Erdene","year":"2021","unstructured":"Bum-Erdene, K., Liu, D., Xu, D., Ghozayel, M. K. & Meroueh, S. O. Design and synthesis of fragment derivatives with a unique inhibition mechanism of the Upar.uPA Interaction. ACS Med Chem Lett 12, 60\u201366. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00422 (2021).","journal-title":"ACS Med Chem Lett"},{"key":"43934_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cmdc.202000558","volume":"16","author":"D Xu","year":"2021","unstructured":"Xu, D. et al. Small-molecule inhibition of the uPAR uPA interaction by conformational selection. ChemMedChem 16, 377\u2013387. https:\/\/doi.org\/10.1002\/cmdc.202000558 (2021).","journal-title":"ChemMedChem"},{"key":"43934_CR52","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1021\/jm020254q","volume":"45","author":"N Schmiedeberg","year":"2002","unstructured":"Schmiedeberg, N. et al. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 45, 4984\u20134994. https:\/\/doi.org\/10.1021\/jm020254q (2002).","journal-title":"J Med Chem"},{"key":"43934_CR53","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.1073\/pnas.91.15.7129","volume":"91","author":"RJ Goodson","year":"1994","unstructured":"Goodson, R. J., Doyle, M. V., Kaufman, S. E. & Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 91, 7129\u20137133. https:\/\/doi.org\/10.1073\/pnas.91.15.7129 (1994).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43934_CR54","doi-asserted-by":"publisher","first-page":"12157","DOI":"10.1021\/bi010662g","volume":"40","author":"M Ploug","year":"2001","unstructured":"Ploug, M. et al. Peptide-derived antagonists of the urokinase receptor affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157\u201312168 (2001).","journal-title":"Biochemistry"},{"key":"43934_CR55","doi-asserted-by":"publisher","first-page":"15044","DOI":"10.1021\/bi048706j","volume":"43","author":"TJ J\u00f8rgensen","year":"2004","unstructured":"J\u00f8rgensen, T. J., G\u00e5rdsvoll, H., Dan\u00f8, K., Roepstorff, P. & Ploug, M. Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry 43, 15044\u201315057. https:\/\/doi.org\/10.1021\/bi048706j (2004).","journal-title":"Biochemistry"},{"key":"43934_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2021.799533","author":"TE Jeppesen","year":"2021","unstructured":"Jeppesen, T. E. et al. Optimization and evaluation of Al18F labeling using a nOTA\u2014or RESCA1-conjugated AE105 peptide antagonist of uPAR. Front Nuclear Med https:\/\/doi.org\/10.3389\/fnume.2021.799533 (2021).","journal-title":"Front Nuclear Med"},{"key":"43934_CR57","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/sj.emboj.7600635","volume":"24","author":"P Llinas","year":"2005","unstructured":"Llinas, P. et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. Embo j 24, 1655\u20131663. https:\/\/doi.org\/10.1038\/sj.emboj.7600635 (2005).","journal-title":"Embo j"},{"key":"43934_CR58","doi-asserted-by":"publisher","first-page":"618","DOI":"10.7150\/thno.6810","volume":"3","author":"M Persson","year":"2013","unstructured":"Persson, M. et al. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: Comparative in vitro and in vivo studies. Theranostics 3, 618\u2013632. https:\/\/doi.org\/10.7150\/thno.6810 (2013).","journal-title":"Theranostics"},{"key":"43934_CR59","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.nucmedbio.2011.10.011","volume":"39","author":"M Persson","year":"2012","unstructured":"Persson, M., Madsen, J., Ostergaard, S., Ploug, M. & Kjaer, A. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 39, 560\u2013569. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.10.011 (2012).","journal-title":"Nucl Med Biol"},{"key":"43934_CR60","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2174\/138945011797635812","volume":"12","author":"MC Kriegbaum","year":"2011","unstructured":"Kriegbaum, M. C. et al. Rational targeting of the urokinase receptor (uPAR): Development of antagonists and non-invasive imaging probes. Curr Drug Targets 12, 1711\u20131728. https:\/\/doi.org\/10.2174\/138945011797635812 (2011).","journal-title":"Curr Drug Targets"},{"key":"43934_CR61","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.8b00669","author":"S Kurbegovic","year":"2018","unstructured":"Kurbegovic, S. et al. Molecular targeted NIR-II probe for image-guided brain tumor surgery. Bioconjugate Chem https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00669 (2018).","journal-title":"Bioconjugate Chem"},{"key":"43934_CR62","doi-asserted-by":"publisher","first-page":"10147428","DOI":"10.1371\/journal.pone.0147428","volume":"11","author":"K Juhl","year":"2016","unstructured":"Juhl, K., Christensen, A., Persson, M., Ploug, M. & Kjaer, A. Peptide-based optical uPAR imaging for surgery: In vivo testing of ICG-Glu-Glu-AE105. PLoS One 11, 10147428. https:\/\/doi.org\/10.1371\/journal.pone.0147428 (2016).","journal-title":"PLoS One"},{"key":"43934_CR63","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1007\/s00018-019-03150-0","volume":"76","author":"A Prestel","year":"2019","unstructured":"Prestel, A. et al. The PCNA interaction motifs revisited: Thinking outside the PIP-box. Cell Mol Life Sci 76, 4923\u20134943. https:\/\/doi.org\/10.1007\/s00018-019-03150-0 (2019).","journal-title":"Cell Mol Life Sci"},{"key":"43934_CR64","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1021\/bi972787k","volume":"37","author":"M Ploug","year":"1998","unstructured":"Ploug, M., Ostergaard, S., Hansen, L. B., Holm, A. & Dan\u00f8, K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 37, 3612\u20133622. https:\/\/doi.org\/10.1021\/bi972787k (1998).","journal-title":"Biochemistry"},{"key":"43934_CR65","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1073\/pnas.90.3.838","volume":"90","author":"B Forood","year":"1993","unstructured":"Forood, B., Feliciano, E. J. & Nambiar, K. P. Stabilization of alpha-helical structures in short peptides via end capping. Proc Natl Acad Sci U S A 90, 838\u2013842. https:\/\/doi.org\/10.1073\/pnas.90.3.838 (1993).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"43934_CR66","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/326563a0","volume":"326","author":"KR Shoemaker","year":"1987","unstructured":"Shoemaker, K. R., Kim, P. S., York, E. J., Stewart, J. M. & Baldwin, R. L. Tests of the helix dipole model for stabilization of alpha-helices. Nature 326, 563\u2013567. https:\/\/doi.org\/10.1038\/326563a0 (1987).","journal-title":"Nature"},{"key":"43934_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prot.340050102","volume":"5","author":"R Fairman","year":"1989","unstructured":"Fairman, R., Shoemaker, K. R., York, E. J., Stewart, J. M. & Baldwin, R. L. Further studies of the helix dipole model: Effects of a free alpha-NH3+ or alpha-COO- group on helix stability. Proteins 5, 1\u20137. https:\/\/doi.org\/10.1002\/prot.340050102 (1989).","journal-title":"Proteins"},{"key":"43934_CR68","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1110\/ps.073365408","volume":"17","author":"DS Weinstock","year":"2008","unstructured":"Weinstock, D. S., Narayanan, C., Baum, J. & Levy, R. M. Correlation between 13Calpha chemical shifts and helix content of peptide ensembles. Protein Sci 17, 950\u2013954. https:\/\/doi.org\/10.1110\/ps.073365408 (2008).","journal-title":"Protein Sci"},{"key":"43934_CR69","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.bpj.2016.04.015","volume":"110","author":"H Meuzelaar","year":"2016","unstructured":"Meuzelaar, H., Vreede, J. & Woutersen, S. Influence of Glu\/Arg, Asp\/Arg, and Glu\/Lys salt bridges on \u03b1-helical stability and folding kinetics. Biophys J 110, 2328\u20132341. https:\/\/doi.org\/10.1016\/j.bpj.2016.04.015 (2016).","journal-title":"Biophys J"},{"key":"43934_CR70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/prot.340170110","volume":"17","author":"Y Bai","year":"1993","unstructured":"Bai, Y., Milne, J. S., Mayne, L. & Englander, S. W. Primary structure effects on peptide group hydrogen exchange. Proteins 17, 75\u201386. https:\/\/doi.org\/10.1002\/prot.340170110 (1993).","journal-title":"Proteins"},{"key":"43934_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s42003-023-04445-6","volume":"6","author":"S Elkjaer","year":"2023","unstructured":"Elkjaer, S. et al. Evolutionary fine-tuning of residual helix structure in disordered proteins manifests in complex structure and lifetime. Commun Biol 6, 63. https:\/\/doi.org\/10.1038\/s42003-023-04445-6 (2023).","journal-title":"Commun Biol"},{"key":"43934_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.116.178970","volume":"58","author":"D Skovgaard","year":"2017","unstructured":"Skovgaard, D. et al. Safety, dosimetry, and tumor detection ability of (68)Ga-NOTA-AE105: First-in-human study of a novel radioligand for uPAR PET imaging. J Nucl Med 58, 379\u2013386. https:\/\/doi.org\/10.2967\/jnumed.116.178970 (2017).","journal-title":"J Nucl Med"},{"key":"43934_CR73","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/1078-0432.CCR-07-4434","volume":"14","author":"ZB Li","year":"2008","unstructured":"Li, Z. B. et al. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 14, 4758\u20134766. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4434 (2008).","journal-title":"Clin Cancer Res"},{"key":"43934_CR74","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1039\/d1cs01175h","volume":"51","author":"J Whisenant","year":"2022","unstructured":"Whisenant, J. & Burgess, K. Synthetic helical peptide capping strategies. Chem Soc Rev 51, 5795\u20135804. https:\/\/doi.org\/10.1039\/d1cs01175h (2022).","journal-title":"Chem Soc Rev"},{"key":"43934_CR75","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pep.2003.12.002","volume":"34","author":"H Gardsvoll","year":"2004","unstructured":"Gardsvoll, H., Werner, F., Sondergaard, L., Dano, K. & Ploug, M. Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. Protein Expr Purif 34, 284\u2013295. https:\/\/doi.org\/10.1016\/j.pep.2003.12.002 (2004).","journal-title":"Protein Expr Purif"},{"key":"43934_CR76","doi-asserted-by":"publisher","first-page":"19260","DOI":"10.1074\/jbc.M513583200","volume":"281","author":"H Gardsvoll","year":"2006","unstructured":"Gardsvoll, H. et al. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem 281, 19260\u201319272. https:\/\/doi.org\/10.1074\/jbc.M513583200 (2006).","journal-title":"J Biol Chem"},{"key":"43934_CR77","doi-asserted-by":"crossref","unstructured":"Julie, M., Leth, M., Ploug, B. B. & Kragelund, K. S. Intrinsically disordered proteins methods and protocols determination of binding kinetics of intrinsically disordered proteins by surface plasmon resonance. Springer US New York NY. 611\u2013627 (2020).","DOI":"10.1007\/978-1-0716-0524-0_31"},{"key":"43934_CR78","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1002\/anie.201100370","volume":"50","author":"K Kazimierczuk","year":"2011","unstructured":"Kazimierczuk, K. & Orekhov, V. Y. Accelerated NMR spectroscopy by using compressed sensing. Angew Chem Int Ed Engl 50, 5556\u20135559. https:\/\/doi.org\/10.1002\/anie.201100370 (2011).","journal-title":"Angew Chem Int Ed Engl"},{"key":"43934_CR79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00197809","volume":"6","author":"F Delaglio","year":"1995","unstructured":"Delaglio, F. et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 6, 277\u2013293. https:\/\/doi.org\/10.1007\/BF00197809 (1995).","journal-title":"J Biomol NMR"},{"key":"43934_CR80","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/prot.20449","volume":"59","author":"WF Vranken","year":"2005","unstructured":"Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: Development of a software pipeline. Proteins 59, 687\u2013696. https:\/\/doi.org\/10.1002\/prot.20449 (2005).","journal-title":"Proteins"},{"key":"43934_CR81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10858-011-9508-2","volume":"50","author":"M Kjaergaard","year":"2011","unstructured":"Kjaergaard, M. & Poulsen, F. M. Sequence correction of random coil chemical shifts: Correlation between neighbor correction factors and changes in the Ramachandran distribution. J Biomol NMR 50, 157\u2013165. https:\/\/doi.org\/10.1007\/s10858-011-9508-2 (2011).","journal-title":"J Biomol NMR"},{"key":"43934_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167855","volume":"434","author":"AL Gr\u00f8nnemose","year":"2022","unstructured":"Gr\u00f8nnemose, A. L., \u00d8sterlund, E. C., Otzen, D. E. & J\u00f8rgensen, T. J. D. EGCG has dual and opposing effects on the N-terminal region of self-associating \u03b1-synuclein oligomers. J Mol Biol 434, 167855. https:\/\/doi.org\/10.1016\/j.jmb.2022.167855 (2022).","journal-title":"J Mol Biol"},{"key":"43934_CR83","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s13361-013-0727-5","volume":"24","author":"M Guttman","year":"2013","unstructured":"Guttman, M., Weis, D. D., Engen, J. R. & Lee, K. K. Analysis of overlapped and noisy hydrogen\/deuterium exchange mass spectra. J Am Soc Mass Spectrom 24, 1906\u20131912. https:\/\/doi.org\/10.1007\/s13361-013-0727-5 (2013).","journal-title":"J Am Soc Mass Spectrom"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43934-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43934-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43934-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:27:54Z","timestamp":1700267274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43934-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43934"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43934-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andreas Kj\u00e6r is a co-founder of Curasight and FluoGuide. All other authors do not have any competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17248"}}